mRNA Vaccines in Treatment Tumor: Advancement and Challenges
DOI:
https://doi.org/10.62051/bswkyf73Keywords:
mRNA; cancer vaccine; non-virus delivery; nanoparticles.Abstract
Immunotherapy has become a well-known cancer treatment method recently. The expeditious development of COVID-19 vaccines has made the extensive use of messenger RNA (mRNA) vaccines possible, and strikingly increased research data have been devoted to exploiting the potential of mRNA vaccines as preclinical and clinical treatments for cancer. mRNA cancer vaccines can stimulate durable and targeted immune responses against tumor antigens (TAs). Despite the promising future of mRNA vaccines, some challenges remain, including mRNA instability and safety concerns. It is possible to improve mRNA's stability, translation efficiency, and immune-stimulating qualities by changing its components. Another main challenge facing the field of mRNA therapy is to improve the effectiveness delivery systems. This review begins with an introduction to the immunological mechanism underlying mRNA cancer vaccines. It then focuses on discussing the subject of improving the efficacy of mRNA cancer vaccines via two main approaches: optimization of mRNA structural and improvement of delivery system.
Downloads
References
Lorentzen C L, Haanen J B, Met Ö, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol, 2022, 23 (10): e450 - e458.
Gupta M, Wahi A, Sharma P, et al. Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. Vaccines (Basel), 2022, 10 (12).
Vishweshwaraiah Y L, Dokholyan N V. mRNA vaccines for cancer immunotherapy. Front Immunol, 2022, 13: 1029069.
Kudla G, Lipinski L, Caffin F, et al. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol, 2006, 4 (6): e180.
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov, 2014, 13 (10): 759 - 80.
Karikó K, Muramatsu H, Welsh F A, et al. Incorporation of pseudo uridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther, 2008, 16 (11): 1833 - 40.
Thess A, Grund S, Mui B L, et al. Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals. Mol Ther, 2015, 23 (9): 1456 - 64.
Sittplangkoon C, Alameh M G, Weissman D, et al. mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model. Front Immunol, 2022, 13: 983000.
Ramos Da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med, 2023, 15 (686): eabn3464.
Verbeke R, Lentacker I, Breckpot K, et al. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. ACS Nano, 2019, 13 (2): 1655 - 1669.
Huang P, Jiang L, Pan H, et al. An Integrated Polymeric mRNA Vaccine without Inflammation Side Effects for Cellular Immunity Mediated Cancer Therapy. Adv Mater, 2023, 35 (3): e2207471.
Chen J, Ye Z, Huang C, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci U S A, 2022, 119 (34): e2207841119.
Yang W, Mixich L, Boonstra E, et al. Polymer-Based mRNA Delivery Strategies for Advanced Therapies. Adv Healthc Mater, 2023, 12 (15): e2202688.
Ke X, Shelton L, Hu Y, et al. Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells. ACS Appl Mater Interfaces, 2020, 12 (32): 35835 - 35844.
Savar N S, Vallet T, Arashkia A, et al. Packaging, Purification, and Titration of Replication-Deficient Semliki Forest Virus-Derived Particles as a Self-Amplifying mRNA Vaccine Vector. Iran Biomed J, 2022, 26 (4): 269 - 78.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
